Answers are grounded in this paper and cite their sources.
The overexpression and aberrant glycosylation of MUC1 is associated with a wide variety of cancers, making it an ideal target for immunotherapeutic strategies. This review highlights the main avenues of research in this field, focusing on adenocarcinomas, from the preclinical to clinical; the problems and possible solutions associated with each approach; and speculates on the direction of MUC1 immunotherapeutic research over the next 5-10 years.
No takes yet. Share an insight, caveat, or question.
Beatson et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: